Drug intelligence / Profile preview

Bifilact

Development stage: Phase 3
Modality: Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifilact is a probiotic preparation composed of beneficial bacterial strains, including *Lactobacillus acidophilus* (e.g., LAC-361) and *Bifidobacterium longum* (e.g., BB-536). It has been investigated for its role in modulating gut microbiota and preventing or reducing conditions such as radiation-induced diarrhea, gastroduodenitis, ulcer disease, and dysbacteriosis. It is classified as a dietary supplement and nutraceutical.

Brand names: Bifilact

Beyond the preview

Go deeper on Bifilact.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifilact.

Explore the full profile